tation for metastatic breast cancer: Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000.4. Gluck S, Crump M. A Randomised Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy versus Standard Therapy in Women with Metastatic Breast Cancer Who Have Responded to...
- 《Clinical Breast Cancer》 被引量: 315发表: 2012年 Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast c... In order to examine the efficacy and safety of nanoparticle albumin-bound ...
Molecular Detection of Micrometastatic Breast Cancer in Histopathology—Negative Axillary Lymph Nodes Fails to Predict Breast Cancer Recurrence: A Final An... ET AL.: " Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recu...
Final results of a 2:1 control-case observational study using interferon beta and interleukin-2, in addition to first-line hormone therapy, in estrogen receptor-positive, endocrine-responsive metastatic breast cancer patients 来自 万方 喜欢 0 阅读量: 2 ...
Taxane/cisplatin combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a docetaxel/cisplatin combination. The toxicity in favor of docetaxel/cisplatin warrants future first-line clinical trials. metastatic breast cancer, taxanes, platinum, hemotherapy Topic:...
The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity.Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but n...
We aimed to compare the additional benefit of gemcitabine when combined with vinorelbine above that of standard vinorelbine treatment in patients with metastatic breast cancer. In this phase III, multicentre, open-label, randomised study, 252 women with locally recurrent and metastatic breast cancer who...
Final results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)Background SFX-01 is a proprietary synthetic pharmaceutical product based upon a stabilised sulforaphane. In preclinical models SFX-01 inhibits the activity of cancer stem-like ...
The availability of human epidermal growth factor receptor 2 (HER2)-targeted therapy has dramatically changed the prognosis for patients with HER2-positive early breast cancer. Trastuzumab added to chemotherapy has been associated with improved pathologic complete response (pCR) rates and long-term surviv...
KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer with prior HER2-targeted therapy and chemotherapy. Patients received T-DM1 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease...